Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-05-08

Clinical Trial Update: Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 efficacy and safety results for MP-513 in combination with a sulfonylurea in adults with Type 2 Diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MP-513

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2014-05-08